Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroOne Medical Technologies Corporation filings document the public-company records of a Nasdaq-listed medical technology issuer developing thin-film electrode and ablation systems for neurological procedures. Current reports and proxy materials disclose operating results, regulatory and clinical update categories, capital-structure actions, governance matters and stockholder voting items.
The company’s SEC record includes Form 8-K disclosures for financial results, Nasdaq listing compliance, certificate amendments, reverse stock split actions, officer and compensation matters, and annual-meeting scheduling. Its definitive proxy statement covers director elections, auditor ratification, equity incentive plan amendments, stockholder proposals and other governance votes tied to NeuroOne’s common stock.
Brian and Barbara Pratt report beneficial ownership of 1,085,934 shares of NeuroOne Medical Technologies Corporation common stock, representing 12.5% of the company’s outstanding common shares. All shares are held in a joint account with a spouse, giving each shared voting and shared dispositive power and no sole authority.
The 12.5% interest is calculated using 8,702,982 NeuroOne common shares outstanding as of June 10, 2026, as referenced from a recent company report. Brian and Barbara Pratt have entered into a Joint Filing Agreement dated April 21, 2026, to report this ownership together.
Brian Pratt, a more-than-10% owner of NeuroOne Medical Technologies Corp, reported beneficial ownership of 1,085,934 shares of common stock. These shares are held in a joint account with his spouse, reflecting direct beneficial ownership; the filing records existing holdings only, with no new buy or sell transaction.
NEUROONE MEDICAL TECHNOLOGIES Corp Market Development Director Mark Christianson reported an open-market sale of 10,000 shares of Common Stock at an average price of $3.1773 per share. After this transaction, he directly holds 20,692 shares, indicating he retained a substantial remaining equity position in the company.
Mark A. Christianson filed a Form 144 to sell up to 10,000 shares of Common Stock of NeuroOne Med Tech. The form lists an aggregate amount of $33,400.00 and records multiple sales during March 2026, including 15,363 shares on 03/30/2026 for $11,053.07 and other smaller dispositions earlier in March.
NeuroOne Medical Technologies Corporation supplements its prior prospectuses to increase the amount of securities it may sell under its at‑the‑market sales agreement with JonesTrading to $13,400,000. The Sales Agreement, dated December 21, 2022, authorizes sales of common stock through Jones as sales agent in "at the market offerings." The supplement states the company previously sold approximately $8,359,586 under the Sales Agreement and that the aggregate market value of outstanding common stock held by non‑affiliates was $41.48 million, calculated using 8,117,474 non‑affiliate shares and a price of $5.11 per share as of April 22, 2026.
NeuroOne Medical Technologies Corporation is updating its at-the-market stock offering, filing a Prospectus Supplement for the offer and sale of up to $13.4 million of common shares through JonesTrading under its existing Capital on Demand Sales Agreement.
The shares will be issued under an effective registration statement, with sales made only by means of the updated prospectus. Honigman LLP provided a legal opinion on the validity of the shares, which is included as an exhibit to this report.
NeuroOne Medical Technologies Corporation restated its March 31, 2026 quarter after discovering duplicated product revenue and cost entries on modified customer purchase orders. The correction reduced product revenue by $529,135 and gross profit by $296,353 for the three and six months ended March 31, 2026, and lowered total assets and stockholders’ equity by $296,353. The company reported a six‑month net loss of $3.8 million and ended March 31, 2026 with $2.8 million in cash and cash equivalents. Management states the errors were not due to intentional misconduct and is implementing stronger purchase order controls. The filing also reiterates substantial doubt about NeuroOne’s ability to continue as a going concern, noting cumulative losses of about $82.4 million and projecting that current cash, planned revenue from its Zimmer distribution agreement, and cost reductions will fund operations only through September 2026.
NeuroOne Medical Technologies announced that investors should no longer rely on its interim financial statements for the quarter ended March 31, 2026 because of revenue-recognition errors tied to modified customer purchase orders. The company will amend and restate its Form 10-Q and related disclosures.
The errors caused revenue and accounts receivable to be overstated by an estimated $529,000, gross profit to be overstated by about $296,000, and operating and net loss to be understated by about $296,000. Total assets were overstated by $296,000 and inventory understated by $233,000. The company attributes the issue in part to inadequately designed and implemented internal controls, but states that no intentional misconduct by management or employees was involved.
In the accompanying press release, NeuroOne notes the error reflects a one-time revenue overstatement of approximately $0.5 million against initially reported quarterly revenue of $2.4 million, with no impact on prior periods or cash as of March 31, 2026. The company says ongoing business activities are not affected and reaffirms product revenue guidance of at least $10.5 million for fiscal 2026.
NeuroOne Medical Technologies reported higher product revenue but continued losses and a going concern warning. For the quarter ended March 31, 2026, product revenue was $2.39 million, up from $1.39 million a year earlier, with six‑month product revenue of $5.28 million.
The company posted a quarterly net loss of $2.09 million and a six‑month net loss of $3.52 million, widening from $0.49 million in the prior‑year period. Cash and cash equivalents were $2.8 million, after $4.44 million of operating cash outflows in six months.
Management states there is substantial doubt about NeuroOne’s ability to continue as a going concern beyond its current runway, which it believes extends through September 2026, absent additional capital. A 1‑for‑6 reverse stock split became effective in April 2026, and a March 2026 private placement raised $670,400. Revenue remains highly concentrated in a single customer under the Zimmer distribution relationship.
NeuroOne Medical Technologies reported fiscal second quarter 2026 results for the period ended March 31, 2026. Product revenue reached $2.4 million, up 72% from $1.4 million a year earlier, driven by higher sales of OneRF products, and first-half product revenue grew to $5.3 million from $4.7 million.
Product gross margin in the quarter was 53.8%, with product gross profit of $1.3 million. The company recorded a quarterly net loss of $2.1 million, or $0.25 per basic and diluted share, compared with a $2.3 million net loss in the prior-year quarter.
As of March 31, 2026, NeuroOne held $2.8 million in cash and cash equivalents and $2.4 million in accounts receivable, with working capital of $5.7 million and no debt outstanding. Management highlighted 16 completed OneRF Trigeminal Neuralgia cases with all patients reportedly pain free and ongoing development across brain ablation, drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.